{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:26:59Z","timestamp":1790263619558,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10620-026-09672-5","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T16:20:04Z","timestamp":1768234804000},"page":"2468-2475","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of Type 2 Diabetes Mellitus on Liver Fibrosis and Hepatic Steatosis in Patients with Primary Biliary Cholangitis: A Longitudinal Study"],"prefix":"10.1007","volume":"71","author":[{"given":"Elizabeth E.","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Lammert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Vuppalanchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"9672_CR1","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1053\/hupa.2002.128060","volume":"33","author":"R Saxena","year":"2002","unstructured":"Saxena R, Hytiroglou P, Thung SN et al. Destruction of canals of hering in primary biliary cirrhosis. Hum Pathol 2002;33:983\u2013988.","journal-title":"Hum Pathol"},{"key":"9672_CR2","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/hep.32117","volume":"75","author":"KD Lindor","year":"2022","unstructured":"Lindor KD, Bowlus CL, Boyer J et al. Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases. Hepatology 2022;75:1012\u20131013.","journal-title":"Hepatology"},{"key":"9672_CR3","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the L. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017;67:145\u2013172.","DOI":"10.1016\/j.jhep.2017.03.022"},{"key":"9672_CR4","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.14309\/ajg.0000000000000557","volume":"115","author":"CF Murillo Perez","year":"2020","unstructured":"Murillo Perez CF, Harms MH, Lindor KD et al. Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase. Am J Gastroenterol 2020;115:1066\u20131074.","journal-title":"Am J Gastroenterol"},{"key":"9672_CR5","doi-asserted-by":"publisher","first-page":"232","DOI":"10.14309\/ajg.0000000000002070","volume":"118","author":"KV Kowdley","year":"2023","unstructured":"Kowdley KV, Bowlus CL, Levy C et al. Application of the latest advances in evidence-based medicine in primary biliary cholangitis. Am J Gastroenterol 2023;118:232\u2013242.","journal-title":"Am J Gastroenterol"},{"key":"9672_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101168","volume":"6","author":"SB Roberts","year":"2024","unstructured":"Roberts SB, Choi WJ, Worobetz L et al. Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis. JHEP Rep 2024;6:101168.","journal-title":"JHEP Rep"},{"key":"9672_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/HEP.0000000000000529","volume":"79","author":"C Corpechot","year":"2024","unstructured":"Corpechot C, Lemoinne S, Soret PA et al. Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain? Hepatology 2024;79:39\u201348.","journal-title":"Hepatology"},{"key":"9672_CR8","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s12016-015-8516-5","volume":"50","author":"F Yang","year":"2016","unstructured":"Yang F, Wang Q, Wang Z et al. The natural history and prognosis of primary biliary cirrhosis with clinical features of autoimmune hepatitis. Clin Rev Allergy Immunol 2016;50:114\u2013123.","journal-title":"Clin Rev Allergy Immunol"},{"key":"9672_CR9","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/hep.25599","volume":"56","author":"C Corpechot","year":"2012","unstructured":"Corpechot C, Carrat F, Poujol-Robert A et al. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology 2012;56:198\u2013208.","journal-title":"Hepatology"},{"key":"9672_CR10","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3350\/cmh.2012.18.4.375","volume":"18","author":"HE Jung","year":"2012","unstructured":"Jung HE, Jang JY, Jeong SW et al. Prognostic indicators in primary biliary cirrhosis: significance of revised IAHG (International Autoimmune Hepatitis Group) score. Clin Mol Hepatol 2012;18:375\u2013382.","journal-title":"Clin Mol Hepatol"},{"key":"9672_CR11","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","volume":"29","author":"ML Teng","year":"2023","unstructured":"Teng ML, Ng CH, Huang DQ et al. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol 2023;29:S32\u2013S42.","journal-title":"Clin Mol Hepatol"},{"key":"9672_CR12","doi-asserted-by":"publisher","first-page":"372","DOI":"10.2337\/dc17-1902","volume":"41","author":"A Mantovani","year":"2018","unstructured":"Mantovani A, Byrne CD, Bonora E et al. nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. Diabetes Care 2018;41:372\u2013382.","journal-title":"Diabetes Care"},{"key":"9672_CR13","doi-asserted-by":"publisher","first-page":"3920196","DOI":"10.1155\/2020\/3920196","volume":"2020","author":"DM Tanase","year":"2020","unstructured":"Tanase DM, Gosav EM, Costea CF et al. The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD). J Diabetes Res 2020;2020:3920196.","journal-title":"J Diabetes Res"},{"key":"9672_CR14","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1097\/MCG.0b013e318261e659","volume":"47","author":"M Hindi","year":"2013","unstructured":"Hindi M, Levy C, Couto CA et al. Primary biliary cirrhosis is more severe in overweight patients. J Clin Gastroenterol 2013;47:e28-32.","journal-title":"J Clin Gastroenterol"},{"key":"9672_CR15","doi-asserted-by":"publisher","first-page":"6174","DOI":"10.12659\/MSM.916107","volume":"25","author":"X Liu","year":"2019","unstructured":"Liu X, Xu H, Zhan M et al. The potential effects of diabetes mellitus on liver fibrosis in patients with primary biliary cholangitis. Med Sci Monit 2019;25:6174\u20136180.","journal-title":"Med Sci Monit"},{"key":"9672_CR16","doi-asserted-by":"crossref","unstructured":"Vallet-Pichard A, Mallet V, Pol S. FIB-4: a simple, inexpensive and accurate marker of fibrosis in HCV-infected patients. Hepatology 2006;44:769; author reply 769\u201370.","DOI":"10.1002\/hep.21334"},{"key":"9672_CR17","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/jhep.2003.50346","volume":"38","author":"CT Wai","year":"2003","unstructured":"Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518\u2013526.","journal-title":"Hepatology"},{"key":"9672_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.04.043","volume":"17","author":"MS Siddiqui","year":"2019","unstructured":"Siddiqui MS, Vuppalanchi R, Van Natta ML et al. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2019;17:e2.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9672_CR19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/hep.29489","volume":"67","author":"R Vuppalanchi","year":"2018","unstructured":"Vuppalanchi R, Siddiqui MS, Van Natta ML et al. Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease. Hepatology 2018;67:134\u2013144.","journal-title":"Hepatology"},{"key":"9672_CR20","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1002\/hep.31810","volume":"74","author":"L Cristoferi","year":"2021","unstructured":"Cristoferi L, Calvaruso V, Overi D et al. Accuracy of transient elastography in assessing fibrosis at diagnosis in naive patients with primary biliary cholangitis: a dual cut-off approach. Hepatology 2021;74:1496\u20131508.","journal-title":"Hepatology"},{"key":"9672_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.06.035","volume":"22","author":"L Lam","year":"2024","unstructured":"Lam L, Soret PA, Lemoinne S et al. Dynamics of liver stiffness measurement and clinical course of primary biliary cholangitis. Clin Gastroenterol Hepatol 2024;22:e2.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9672_CR22","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/j.jhep.2022.06.017","volume":"77","author":"C Corpechot","year":"2022","unstructured":"Corpechot C, Carrat F, Gaouar F et al. Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. J Hepatol 2022;77:1545\u20131553.","journal-title":"J Hepatol"},{"key":"9672_CR23","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/hep.30145","volume":"69","author":"KD Lindor","year":"2019","unstructured":"Lindor KD, Bowlus CL, Boyer J et al. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2019;69:394\u2013419.","journal-title":"Hepatology"},{"key":"9672_CR24","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017;67:145\u2013172.","DOI":"10.1016\/j.jhep.2017.03.022"},{"key":"9672_CR25","doi-asserted-by":"publisher","first-page":"995","DOI":"10.14309\/ajg.0000000000000116","volume":"114","author":"R Vuppalanchi","year":"2019","unstructured":"Vuppalanchi R, Weber R, Russell S et al. Is fasting necessary for individuals with nonalcoholic fatty liver disease to undergo vibration-controlled transient elastography? Am J Gastroenterol 2019;114:995\u2013997.","journal-title":"Am J Gastroenterol"},{"key":"9672_CR26","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/hep.28843","volume":"65","author":"S Petta","year":"2017","unstructured":"Petta S, Wong VW, Camma C et al. Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. Hepatology 2017;65:1145\u20131155.","journal-title":"Hepatology"},{"key":"9672_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.732929","volume":"12","author":"RP Cunningham","year":"2021","unstructured":"Cunningham RP, Porat-Shliom N. Liver zonation - revisiting old questions with new technologies. Front Physiol 2021;12:732929.","journal-title":"Front Physiol"},{"key":"9672_CR28","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1053\/j.gastro.2014.07.056","volume":"147","author":"MM Yeh","year":"2014","unstructured":"Yeh MM, Brunt EM. Pathological features of fatty liver disease. Gastroenterology 2014;147:754\u2013764.","journal-title":"Gastroenterology"},{"key":"9672_CR29","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jhep.2008.01.016","volume":"48","author":"N Chalasani","year":"2008","unstructured":"Chalasani N, Wilson L, Kleiner DE et al. Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with nonalcoholic fatty liver disease. J Hepatol 2008;48:829\u2013834.","journal-title":"J Hepatol"},{"key":"9672_CR30","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1007\/PL00002934","volume":"44","author":"NJ Morrish","year":"2001","unstructured":"Morrish NJ, Wang SL, Stevens LK et al. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia 2001;44:S14-21.","journal-title":"Diabetologia"},{"key":"9672_CR31","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/joim.13005","volume":"287","author":"S Zandanell","year":"2020","unstructured":"Zandanell S, Strasser M, Feldman A et al. Low rate of new-onset primary biliary cholangitis in a cohort of anti-mitochondrial antibody-positive subjects over six years of follow-up. J Intern Med 2020;287:395\u2013404.","journal-title":"J Intern Med"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-09672-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-026-09672-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-026-09672-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T02:26:50Z","timestamp":1783909610000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-026-09672-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["9672"],"URL":"https:\/\/doi.org\/10.1007\/s10620-026-09672-5","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"assertion":[{"value":"18 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval\n                      This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The human investigation committee (IRB) of IUPUI approved this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RV: Institutional research is supported by Eli Lilly and Company, Galectin Therapeutics, Takeda, AstraZeneca, Zydus Pharmaceuticals, Gilead Sciences, Kowa Pharmaceuticals, and GlaxoSmithKline. Consultant for Madrigal Pharmaceuticals, Akero Therapeutics, Regeneron, 89 Bio, GSK, Cogent Biosciences, Agios, and Merck in various capacities, including steering committees, data safety monitoring committees, and adjudication committees related to hepatic safety and clinical outcomes.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}